Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.

Alexander Chehrazi-RaffleSally LeongSana AliTane KimSam MelamedXiaochen LiZeynep ZenginLuis MezaNeal ChawlaAmeish GovindarajanDaniela CastroBenjamin MercierHedyeh EbrahimiNazli DizmanNishita TripathiNicolas SayeghAdam RockJames YehSumanta K PalMykola Onyshchenko

Published in: The oncologist (2023)

Latinx patients with mRCC had a shorter PFS treated with frontline nivolumab/ipilimumab compared to their non-Latinx counterparts. No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC.

Keyphrases

metastatic renal cell carcinoma
healthcare
mental health
electronic health record
big data
type diabetes
machine learning
metabolic syndrome
skeletal muscle
case control
insulin resistance
glycemic control
artificial intelligence